时间会记住那些持续向前的人。 继第一季「致敬成长」系列视频之后，北极光创投与创业邦再度携手，推出第二季特别策划。我们 邀请 到 XSKY星辰天合与脑动极光-B(06681.HK) 两家优秀的创业企业走到 台前，分享成长历 程，探讨初心、理想、成长、认知、价值等话题。过程中，投资人既是见证者，也是亲历者与陪伴 者，亦将一同分享他们眼中的成长。 这不仅是一场关于创业的交流，更是对成长的真挚致敬。在这个特别时刻，让我们一同感受成长的 力量，携手创勇者迎接更多挑战。 一场持续十三年的"极夜行军"， 如果你也曾创业，如果你关心医疗与科技的未来， 如果你好奇——一家公司如何在绝望中找到那束"极光"—— 那么，这个故事值得你点开。 脑动极 光，也 曾经历过最艰难的时期，账上资金仅能勉强维持，一支三十余人的团队，在困境中坚 守着一个看似遥远的梦想。 五年后，它却在港交所敲钟，成为"数字疗法第一股"。 这中间究竟发生了什么？ 是运气，还是坚持？ 如何走过至暗时刻？ 数字疗法，听起来像游戏，却要治好阿尔茨海默病、抑郁症…… 它究竟是黑科技，还是另一个泡沫？ 北极光 x 创业邦"致敬成长"往期精彩视频 ⬇️ ⬇️点击观看 听CEO ...

Core Viewpoint - The company, Brainstorm Aurora-B (06681), has seen its stock price increase by over 4%, currently trading at 4.83 HKD with a transaction volume of 48.71 million HKD, following the announcement of a strategic partnership with Macau Kiang Wu Hospital to enhance digital health services for cognitive disorders [1] Group 1 - The company’s subsidiary, Brainstorm Aurora Medical Technology (Macau) Limited, has signed a cooperation agreement with Macau Kiang Wu Hospital to provide digital AI technology services for brain health [1] - The partnership aims to establish a comprehensive health management model covering "hospital-community-home" for cognitive disorder screening, assessment, training, and management in the Macau region [1] - The board believes this collaboration sets a benchmark for the group and opens up the Greater Bay Area market, marking the first flagship project for the group’s digital therapy in the Hong Kong-Macau region [1] Group 2 - The collaboration enriches the company's ecosystem alliance with authoritative medical institutions, complementing a recent national-level project partnership with the National Rehabilitation Aids Research Center under the Ministry of Civil Affairs [1] - This initiative aims to promote the standardization and large-scale application of cognitive digital therapies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 與澳門鏡湖醫院簽署腦健康數字AI技術服務合作協議 本公告乃腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在知會本公司股東及潛在投資者本集團於港澳地區之最新業務發展。 本公司董事會（「董事會」）欣然宣佈，本公司之間接全資附屬公司－腦動極光醫學 科技數智（澳門）有限公司（「腦動極光澳門」），已於近期與澳門鏡湖醫院（「鏡湖 醫院」）正式簽署《腦健康數字AI技術服務合作協議》（「該協議」）。雙方將圍繞認 知障礙的數字篩查、評估、訓練及全程健康管理，在澳門地區建立長期戰略合作 關係，共同構建覆蓋「醫院 － 社區 － 家居」的全鏈條腦健康服務新模式（「本次合 作」）。 一、合作背景 董事會認為，本次合作對本集團 ...

本文源自：金融界AI电报 脑动极光-B(06681.HK)公告，公司与丝路之舟科技有限公司订立战略合作协议，双方将在马来西亚及东 南亚区域围绕认知障碍数字疗法产品的本土化落地、市场推广与科研转化等领域开展深度战略合作，共 同推动数字健康产业发展。根据协议，双方合作包括专项实验室建设：丝路之舟协助本公司在马来西亚 设立"认知障碍数字疗法专项实验室"，协调当地审批、场地规划及设备进口等事宜；本公司提供技术方 案与科研支持，主导研发与运营等。 ...

Core Viewpoint - The stock of Brainstorm Cell Therapeutics Inc. (脑动极光-B) experienced a significant increase of nearly 10%, reaching a peak price of 8.14 HKD per share, with a total market capitalization of approximately 10 billion HKD as of January 8, 2026 [1][2]. Group 1: Stock Performance - The stock opened at 7.46 HKD and reached a maximum price of 8.14 HKD, with a closing price of 7.21 HKD the previous day [2]. - The stock's 52-week high is 17.79 HKD, while the 52-week low is 3.51 HKD [2]. - The trading volume was 39.6 million shares, with an external trading volume of 22.58 million and an internal trading volume of 17.02 million [2]. Group 2: Company Developments - Brainstorm Cell Therapeutics announced on January 7 that it has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2]. - The company, in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has received approval to establish the "Beijing Key Laboratory for Precision Intelligent Diagnosis and Treatment of Mental Disorders" [1][2].

Core Viewpoint - The company, Brainstorm Cell Therapeutics-B (06681), has seen its stock price increase by over 8%, currently trading at 7.75 HKD with a transaction volume of 58.17 million HKD, following the announcement of significant business collaborations aimed at advancing digital therapies for mental health [1] Group 1: Business Collaborations - The company has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to jointly promote the research and commercialization of digital therapy products for mental health [1] - The collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University has led to the establishment of a key laboratory for precision intelligent diagnosis and treatment of mental disorders in Beijing [1] Group 2: Clinical Applications and Network Expansion - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disease medicine, to promote the clinical application of digital therapy products for mental health [1] - The recent partnerships further expand the company's presence in core mental health specialty hospitals across the country, creating a comprehensive commercial network from national flagship centers to regional hubs and key specialty hospitals [1]

Group 1 - The core point of the article highlights that Brainstorm Aurora-B (06681) has deposited shares worth HKD 1.959 billion into Guotai Junan (Hong Kong), representing 20.77% of the total shareholding [2] Group 2 - Brainstorm Aurora has recently signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [3] - The company, in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has successfully applied for the establishment of the "Beijing Key Laboratory for Precision Intelligent Diagnosis and Treatment of Mental Disorders" [3]

Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Collaboration Details - The collaboration with Beijing University Sixth Hospital includes the development of digital therapies and clinical application research, focusing on attention deficit hyperactivity disorder (ADHD) cognitive digital therapy and a precision intelligent diagnosis system for depression [2]. - The research scope encompasses the development of digital therapy products for emotional and behavioral issues across the entire lifecycle, including clinical validation of cognitive digital therapies aimed at improving learning abilities in children with ADHD [2]. - The partnership with Shandong Provincial Mental Health Center involves the development of cognitive screening and intervention systems for mental disorders, as well as methods for capacity training guided by virtual humans [3]. Group 2: Laboratory Establishment - The "Precision Intelligent Diagnosis and Innovation Transformation Key Laboratory for Mental Diseases" has been officially approved, with the company as a core co-construction unit alongside Beijing University Sixth Hospital and the National Engineering Research Center for Software Engineering [3]. - The laboratory will focus on innovation and transformation driven by clinical needs in mental health, integrating clinical medicine, basic research, technology development, and hardware innovation [3]. Group 3: Strategic Positioning - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health facility, to promote the clinical application of digital mental health therapies [4]. - The recent collaborations further expand the company's network within core mental health specialty hospitals across the country, creating a comprehensive commercial landing network from national flagship centers to regional hubs and key specialty hospitals [4]. - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's first-mover advantage in the digital mental health therapy sector, accelerating product development and commercialization processes [4].

Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2][3]. Group 1: Joint Research Content - The research will focus on developing digital therapies and clinical applications, including the effectiveness of cognitive digital therapies for Attention Deficit Hyperactivity Disorder (ADHD) and a precision intelligent diagnosis system for depression [2]. - The research scope includes developing digital therapy products for emotional and behavioral issues across the entire lifecycle, with clinical validation for various age groups [2][3]. Group 2: Commercial Cooperation Content - The company will collaborate on digital technology services for cognitive disorder diagnosis and treatment, establishing a health management system covering elderly, children, and adults [2][3]. Group 3: Establishment of Key Laboratory - The "Beijing Key Laboratory for Precision Intelligent Diagnosis and Transformation of Mental Disorders" has been officially approved, with the company as a core co-builder [4]. - The laboratory will focus on innovation and transformation driven by clinical needs, integrating clinical medicine, basic research, technology development, and hardware innovation [4]. Group 4: Strategic Importance - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the field of digital mental health therapies, accelerating product development and commercialization [5]. - The company aims to continue partnerships with top medical institutions to build a nationwide integrated digital mental health service system [5].

Core Viewpoint - The company has signed a cooperation agreement with Beijing Jianguo Medical Technology Co., Ltd. to advance cognitive digital therapy, focusing on the assessment and training of cognitive functions from January 1, 2026, to December 30, 2026 [1] Group 1 - The collaboration aims to deepen technological exploration and productization in the mental health field, integrating cutting-edge AI algorithms with clinical needs to create more precise and universal digital therapy products [1] - The partnership will contribute to the establishment of industry standards and market normalization, enhancing the company's solution credibility and facilitating nationwide product promotion [2] - The project focuses on enhancing service capabilities in mental health welfare institutions and community settings, significantly expanding the coverage of the company's products and services while creating social benefits and new market growth opportunities [2] Group 2 - The collaboration with Beijing Jianguo Medical strengthens the company's network with national research institutions, accumulating real-world data that will drive algorithm iteration, product optimization, and innovative research and development [2]